Vaderis Therapeutics Secures $152M to Advance HHT Treatment
August 12, 2026, 3:33 pm
Location: Belgium, Flemish Brabant, Meise
Employees: 11-50
Founded date: 2011
Vaderis Therapeutics secured $152 million in Series B funding. This landmark investment propels engasertib, a potential first treatment for rare Hereditary Hemorrhagic Telangiectasia (HHT), into global Phase 3 trials. HHT causes severe nosebleeds, chronic anemia, and dangerous vascular abnormalities, currently lacking approved therapies. EQT Life Sciences, Goldman Sachs Alternatives, and TCGX co-led the round, recognizing engasertib's promising clinical data. This significant capital injection fuels Vaderis's mission to address critical unmet medical needs. It offers substantial hope to HHT patients worldwide. Development accelerates towards potential regulatory approval, marking a pivotal moment in rare disease therapeutics.
Vaderis Therapeutics, a leading biopharmaceutical company, has achieved a significant milestone. The firm closed a $152 million Series B financing round. This capital infusion will accelerate the development of engasertib, their lead therapeutic candidate. Engasertib targets Hereditary Hemorrhagic Telangiectasia (HHT), a debilitating rare vascular disease. This funding commitment underscores investor confidence in Vaderis's innovative science. It highlights the urgent need for new HHT treatments.
EQT Life Sciences made a substantial $17.5 million investment. They joined Life Sciences at Goldman Sachs Alternatives and TCGX as co-leaders of the round. Additional participants included Omega Funds, Perceptive Advisors, Kalehua Capital, Medicxi, and Droia. This diverse group of investors brings considerable experience to the biotech sector. Their collective backing validates Vaderis's strategic direction and clinical progress. The capital raised will support Vaderis through crucial regulatory milestones. It positions engasertib for potential approval in the United States and globally.
Hereditary Hemorrhagic Telangiectasia, or HHT, presents a profound medical challenge. It is a rare genetic disorder. HHT affects approximately 1 in 3,800 individuals. The disease causes abnormal blood vessel formation. This leads to severe, recurrent nosebleeds. Patients often suffer from chronic anemia. More critically, HHT can manifest as life-threatening vascular malformations in vital organs. These include the brain, lungs, and liver. Current treatment options focus solely on symptom management. No approved therapies specifically address the underlying pathology of HHT. This creates an enormous unmet medical need.
Engasertib is Vaderis's flagship program. It represents a potential paradigm shift for HHT patients. Engasertib is an investigational oral selective allosteric inhibitor of AKT1/2. This targeted mechanism aims to correct the root cause of HHT's vascular abnormalities. Previous proof-of-concept data have been highly promising. These findings were published in The New England Journal of Medicine. The data demonstrated clinically meaningful and sustained improvements. Patients with HHT experienced benefits across multiple disease measures. These positive results laid the groundwork for advanced clinical development.
The newly secured funding directly supports the global Phase 3 HEROIC study. HEROIC is a pivotal trial evaluating engasertib in HHT patients. Initiating this Phase 3 study marks a critical advancement. It represents the first Phase 3 trial utilizing a molecule specifically developed for HHT. This global effort underscores Vaderis's commitment to rigorous scientific validation. Success in the HEROIC study could lead to engasertib becoming the first approved therapy for HHT.
EQT Life Sciences brings extensive experience to the Vaderis board. Their expertise supports biotechnology companies through late-stage clinical development. This partnership ensures strategic guidance for Vaderis. It aids in executing the company’s complex development strategy. Such collaborative support is invaluable for a company navigating the final phases of drug approval. The investment reflects EQT's conviction in engasertib's scientific merit. It also acknowledges the significant market opportunity for a breakthrough HHT treatment.
Vaderis Therapeutics operates with a clear mission. They focus on discovering and advancing transformative treatments for rare vascular diseases. The company maintains headquarters in Basel, Switzerland. A US subsidiary in Lincolnshire, Illinois, ensures a strong presence in the American market. This dual-continent structure facilitates global research and development efforts. It also positions Vaderis to address patient needs across major pharmaceutical markets. Their science-driven approach prioritizes unmet medical needs.
The biotechnology investment landscape continues to prioritize rare diseases. Conditions like HHT often lack sufficient research and development. This leads to a severe deficit in treatment options. Investors recognize the immense value in addressing these neglected areas. Successful rare disease therapies can achieve significant market impact. They also offer profound humanitarian benefits. The $152 million Series B round for Vaderis Therapeutics exemplifies this trend. It showcases a sustained commitment to funding innovative solutions for challenging diseases.
The initiation of the HEROIC study signals a defining moment. It offers tangible hope for tens of thousands of HHT patients worldwide. For decades, these individuals have lived without a dedicated therapy. Engasertib's progress represents a beacon of potential relief. Its development could alleviate debilitating symptoms. It may prevent life-threatening complications. The journey to regulatory approval is rigorous. However, the strong clinical data and robust financial backing position Vaderis for success. This represents a pivotal step towards a new era for HHT patient care.
Vaderis Therapeutics, a leading biopharmaceutical company, has achieved a significant milestone. The firm closed a $152 million Series B financing round. This capital infusion will accelerate the development of engasertib, their lead therapeutic candidate. Engasertib targets Hereditary Hemorrhagic Telangiectasia (HHT), a debilitating rare vascular disease. This funding commitment underscores investor confidence in Vaderis's innovative science. It highlights the urgent need for new HHT treatments.
EQT Life Sciences made a substantial $17.5 million investment. They joined Life Sciences at Goldman Sachs Alternatives and TCGX as co-leaders of the round. Additional participants included Omega Funds, Perceptive Advisors, Kalehua Capital, Medicxi, and Droia. This diverse group of investors brings considerable experience to the biotech sector. Their collective backing validates Vaderis's strategic direction and clinical progress. The capital raised will support Vaderis through crucial regulatory milestones. It positions engasertib for potential approval in the United States and globally.
Hereditary Hemorrhagic Telangiectasia, or HHT, presents a profound medical challenge. It is a rare genetic disorder. HHT affects approximately 1 in 3,800 individuals. The disease causes abnormal blood vessel formation. This leads to severe, recurrent nosebleeds. Patients often suffer from chronic anemia. More critically, HHT can manifest as life-threatening vascular malformations in vital organs. These include the brain, lungs, and liver. Current treatment options focus solely on symptom management. No approved therapies specifically address the underlying pathology of HHT. This creates an enormous unmet medical need.
Engasertib is Vaderis's flagship program. It represents a potential paradigm shift for HHT patients. Engasertib is an investigational oral selective allosteric inhibitor of AKT1/2. This targeted mechanism aims to correct the root cause of HHT's vascular abnormalities. Previous proof-of-concept data have been highly promising. These findings were published in The New England Journal of Medicine. The data demonstrated clinically meaningful and sustained improvements. Patients with HHT experienced benefits across multiple disease measures. These positive results laid the groundwork for advanced clinical development.
The newly secured funding directly supports the global Phase 3 HEROIC study. HEROIC is a pivotal trial evaluating engasertib in HHT patients. Initiating this Phase 3 study marks a critical advancement. It represents the first Phase 3 trial utilizing a molecule specifically developed for HHT. This global effort underscores Vaderis's commitment to rigorous scientific validation. Success in the HEROIC study could lead to engasertib becoming the first approved therapy for HHT.
EQT Life Sciences brings extensive experience to the Vaderis board. Their expertise supports biotechnology companies through late-stage clinical development. This partnership ensures strategic guidance for Vaderis. It aids in executing the company’s complex development strategy. Such collaborative support is invaluable for a company navigating the final phases of drug approval. The investment reflects EQT's conviction in engasertib's scientific merit. It also acknowledges the significant market opportunity for a breakthrough HHT treatment.
Vaderis Therapeutics operates with a clear mission. They focus on discovering and advancing transformative treatments for rare vascular diseases. The company maintains headquarters in Basel, Switzerland. A US subsidiary in Lincolnshire, Illinois, ensures a strong presence in the American market. This dual-continent structure facilitates global research and development efforts. It also positions Vaderis to address patient needs across major pharmaceutical markets. Their science-driven approach prioritizes unmet medical needs.
The biotechnology investment landscape continues to prioritize rare diseases. Conditions like HHT often lack sufficient research and development. This leads to a severe deficit in treatment options. Investors recognize the immense value in addressing these neglected areas. Successful rare disease therapies can achieve significant market impact. They also offer profound humanitarian benefits. The $152 million Series B round for Vaderis Therapeutics exemplifies this trend. It showcases a sustained commitment to funding innovative solutions for challenging diseases.
The initiation of the HEROIC study signals a defining moment. It offers tangible hope for tens of thousands of HHT patients worldwide. For decades, these individuals have lived without a dedicated therapy. Engasertib's progress represents a beacon of potential relief. Its development could alleviate debilitating symptoms. It may prevent life-threatening complications. The journey to regulatory approval is rigorous. However, the strong clinical data and robust financial backing position Vaderis for success. This represents a pivotal step towards a new era for HHT patient care.